M. Decatris

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial

Janet E. Brown, Kara‐Louise Royle, Walter M. Gregory et al. · The Lancet Oncology · 2023 · 81 citations · Full text

Medicine, Oncology, Pharmacology +11

A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer

Kenneth J. O’Byrne, Anne Thomas, Ricky A. Sharma et al. · British Journal of Cancer · 2002 · 77 citations · Full text

Medicine, Oncology, Pharmacology +17

High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumours: An effective first-line therapy with minimal toxicity

M. Decatris, P M Wilkinson, Richard Welch et al. · Annals of Oncology · 2000 · 42 citations · Full text

Medicine, Hematology, Oncology +14

Phase II trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy

Santhanam Sundar, R.P. Symonds, M. Decatris et al. · Gynecologic Oncology · 2004 · 29 citations

Medicine, Gynecology, Oncology +16

Melanoma of the gallbladder: appropriate surgical management and review of the literature

Demetris Christou, Nicos Katodritis, M. Decatris et al. · Clinical Case Reports · 2014 · 24 citations · Full text

Medicine, Oncology, Surgery +16